The Russian Ministry of Health has announced the registration of Russia’s first bioanalogue of the Swiss medication “Actemra” (tocilizumab, Roche), developed by the company “Generium,” for the treatment of rheumatoid arthritis. The trade name of the domestic drug is “Complarate”.
This medication is designed to mitigate systemic inflammatory responses and is utilized in the treatment of rheumatoid arthritis, including systemic juvenile idiopathic arthritis. It is also effective in addressing severe COVID-19 cases and life-threatening cytokine release syndrome.
